Plus   Neg

Walt Disney Q2 Results Beat Wall Street Estimates

Media and entertainment giant Walt Disney Co. (DIS), Wednesday reported a second-quarter profit and revenues that trumped Wall Street estimates.

Burbank, California-based Disney's second-quarter profit rose to $5.45 billion or $3.55 per share from $2.94 billion or $1.95 per share last year.

Adjusted earnings for the quarter were $1.61 per share, compared with $1.84 per share last year. On average, 13 analysts polled by Thomson Reuters estimated earnings of $1.59 per share.

Revenues for the quarter grew 3% to $14.92 billion from last year's $14.55 billion last year. Analysts had a consensus revenue estimate of $14.39 billion.

"We're very pleased with our Q2 results and thrilled with the record-breaking success of Avengers: Endgame, which is now the second-highest grossing film of all time and will stream exclusively on Disney+ starting December 11th," said CEO Robert Iger.

On March 20, Disney acquired 21st Century Fox for $71 billion. Disney will now oversee Fox's storied film and television studios as well as stakes in the Sky PLC pay-television company and the Hulu video-streaming service.

Results for the second quarter reflect the consolidation of 11 days of 21st Century Fox and Hulu, with revenues of $373 million and operating income of $25 million.

Media networks segment's revenues were flat at $5.53 billion, while parks and resorts units increased 5% to $6.17 billion.

Studio entertainment revenues dropped 15 percent to $2.13 billion due to s due to a decrease in theatrical and home entertainment distribution results reflecting the success of Black Panther and the continued performance of Star Wars: The Last Jedi in the prior-year quarter. Direct-to-Consumer & International revenues rose 15 percent to $955 million.

DIS closed Wednesday's trading at 134.99, up $1.55 or 1.16% on the NYSE. The stock further gained $0.62 or 0.46% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor. The Federal Trade Commission (FTC) and the New York State Office of the Attorney General jointly filed a complaint in federal court against Vyera Pharmaceuticals, LLC, and its CEO Martin Shkreli for allegedly engaging in anticompetitive schemes in order to maintain a monopoly over the life-saving drug Daraprim. While reporting financial results for the fourth quarter on Tuesday, Lockheed Martin Corp. (LMT) initiated earnings outlook for the full-year 2020, while boosting annual net sales outlook. For fiscal 2020, the company now expects earnings in a range of $23.65 to $23.95 per share. Net sales are now...
Follow RTT